PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
PACBNasdaq
$1.44
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -3.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$440.4M
Enterprise Value
$164.4M
P/E
—
P/S
2.8
P/B
186.1
EV/EBITDA
—
PEG
—
FCF Yield
-26.4%
Dividend Yield
—
Revenue (TTM)
$160.0M
Net Income (TTM)
-$128.6M
Free Cash Flow (TTM)
-$116.2M
Gross Margin
37.5%
Operating Margin
-83.3%
Net Margin
-80.3%
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$276.0M
Return 1Y
+3.6%
Company profile
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. PacBio's Systems conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow.
- CEO
- Christian O. Henry
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 730
- Headquarters
- California
- Website
- pacb.com
Management & directors
- Gibson James R IiSee Remarks
- Farmer MicheleSee Remarks
- Henry Christian OSee Remarks
- Van Oene MarkSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
PACB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$37.2M↑ +0.1%
Diluted EPS-$0.03↓ -97.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | $160.0M |
| Gross profit | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | $45.8M |
| Operating income | -$104.4M | -$210.4M | -$307.2M | -$334.5M | -$474.3M | -$553.9M |
| Net income | $29.4M | -$181.2M | -$314.2M | -$306.7M | -$309.9M | -$546.4M |
| Diluted EPS | $0.17 | -$0.89 | -$1.40 | -$1.21 | -$1.59 | -$1.82 |
| Operating cash flow | $19.5M | -$111.2M | -$263.2M | -$259.2M | -$206.1M | -$111.2M |
| Free cash flow | $18.5M | -$117.1M | -$280.0M | -$268.0M | -$212.2M | -$113.9M |
| Gross margin | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating margin | -132.3% | -161.2% | -239.4% | -166.8% | -308.0% | -346.2% |
| Net margin | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.0M | $40.0M | $39.2M | $37.2M | $39.8M | $38.4M | $44.6M | $37.2M |
| Gross profit | $5.9M | $10.0M | $10.1M | -$1.4M | $14.7M | $15.9M | $16.6M | $12.8M |
| Operating income | -$175.8M | -$64.1M | -$153.0M | -$428.9M | -$44.9M | -$38.9M | -$41.2M | -$8.4M |
| Net income | -$173.3M | -$60.7M | $2.4M | -$426.1M | -$41.9M | -$38.0M | -$40.4M | -$8.3M |
| Diluted EPS | -$0.64 | -$0.22 | -$0.44 | -$1.44 | -$0.14 | -$0.13 | -$0.11 | -$0.03 |
| Operating cash flow | -$54.3M | -$45.5M | -$30.6M | -$44.1M | -$29.4M | -$18.7M | -$19.1M | -$44.7M |
| Free cash flow | -$55.7M | -$46.3M | -$32.3M | -$45.4M | -$29.9M | -$18.8M | -$19.9M | -$47.7M |
| Gross margin | 16.5% | 25.0% | 25.6% | -3.7% | 36.9% | 41.4% | 37.1% | 34.5% |
| Operating margin | -488.3% | -160.3% | -390.1% | -1154.5% | -112.8% | -101.1% | -92.3% | -22.5% |
| Net margin | -481.3% | -151.9% | 6.0% | -1146.8% | -105.4% | -98.9% | -90.4% | -22.3% |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-08 | Gibson Christopher | Award | 57,473 | $0.00 | $0.00 | filing |
| 2026-04-01 | Gibson James R II· See Remarks | Sale | 88,185 | $1.37 | $120,813.45 | filing |
| 2026-03-03 | HENRY CHRISTIAN O· See Remarks | Sale | 12,497 | $1.51 | $18,920.46 | filing |
| 2026-03-03 | Van Oene Mark· See Remarks | Sale | 6,504 | $1.51 | $9,847.06 | filing |
| 2026-03-03 | Farmer Michele· See Remarks | Sale | 2,979 | $1.51 | $4,510.21 | filing |
| 2026-03-03 | Gibson Christopher | Award | 53,913 | $0.00 | $0.00 | filing |
| 2026-02-27 | Van Oene Mark· See Remarks | Award | 500,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Farmer Michele· See Remarks | Award | 89,835 | $0.00 | $0.00 | filing |
| 2026-02-27 | Gibson James R II· See Remarks | Award | 333,848 | $0.00 | $0.00 | filing |
| 2026-02-27 | HENRY CHRISTIAN O· See Remarks | Award | 920,810 | $0.00 | $0.00 | filing |
| 2026-02-18 | HENRY CHRISTIAN O· See Remarks | Sale | 140,874 | $1.63 | $229,483.75 | filing |
| 2026-02-18 | Van Oene Mark· See Remarks | Sale | 55,107 | $1.63 | $89,769.30 | filing |
| 2026-02-18 | Farmer Michele· See Remarks | Sale | 14,952 | $1.63 | $24,356.81 | filing |
| 2026-02-17 | HENRY CHRISTIAN O· See Remarks | Sale | 331,793 | $1.58 | $522,905.77 | filing |
| 2026-02-17 | Van Oene Mark· See Remarks | Sale | 129,790 | $1.58 | $204,549.04 | filing |
| 2026-02-17 | Farmer Michele· See Remarks | Sale | 35,215 | $1.58 | $55,498.84 | filing |
| 2025-08-18 | Van Oene Mark· See Remarks | Sale | 26,836 | $1.31 | $35,182.00 | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.